spacer
home > ebr > spring 2002 > pharmacogenetics and the development of anticancer agents
PUBLICATIONS
European Biopharmaceutical Review

Pharmacogenetics and the Development of Anticancer Agents

The observation that individuals respond differently to the same drug is centuries old, yet only recently has the biological basis for such variation begun to be unravelled. In the field of pharmacogenetics, detailed biological understanding of the pathways by which drugs act and are metabolised, guides high throughput DNA sequencing efforts to reveal variations within genes critical to therapeutic response. Such variance data is used to associate responsiveness to a drug with specific genetic variations, which can then serve as predictive markers to guide drug usage. This article summarises progress in identifying genetic markers that predict the toxicity and efficacy of chemotherapeutic drugs. Several types of markers have been associated with response to a variety of anticancer agents, including DNA polymorphisms, loss of heterozygosity, and RNA expression patterns within tumours. Some genetic features of cancer that provide the basis for these markers are outlined briefly, examples of each type of marker are provided, and the utility of pharmacogenetics throughout the drug development process is discussed.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ann E. Ferentz, Senior Scientist and Manager of Scientific Communications at Variagenics, Inc

Ann Ferentz obtained her BS from Yale University and her PhD in Chemistry from Harvard University. Her subsequent research at Harvard Medical School and the Massachusetts Institute of Technology focused on structural biology and cellular responses to DNA damage.
She is currently a Senior Scientist and Manager of Scientific Communications at Variagenics, a pharmacogenomics company in Cambridge, Massachusetts.

spacer
Ann E. Ferentz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

The Impact of Components on Drug Quality and Risk Mitigation

West Pharmaceutical Services, Inc.

Expectations for quality by regulatory agencies are increasing at a very fast pace, especially for prefilled drug delivery formats, thanks to increased focus on reducing risk to patient safety. The trend has resulted in delays for new drug applications, more recalls of marketed products and even drug shortages if the container system and drug contents are suspect for quality issues. The pharmaceutical market is now requiring manufacturers of containers and components to meet new expectations with a quality culture and very high product reliability. The need to bridge the gap and provide superior quality products has been a driver for manufacturing technology investments, more robust control strategies and the introduction of next generation elastomer components.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement